• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Palisade Bio Inc. filed SEC Form 8-K: Leadership Update

    9/5/25 9:00:42 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PALI alert in real time by email
    false 0001357459 0001357459 2025-09-04 2025-09-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): September 4, 2025

     

    PALISADE BIO, INC.

    (Exact name of Registrant as Specified in Its Charter)

     

    Delaware   001-33672   52-2007292

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    1902 Wright Place

    Suite 200

       
    Carlsbad, California   92008
    (Address of Principal Executive Offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (858) 704-4900

     

    N/A

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.01 per share   PALI   Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    Phantom Equity Plan

     

    On September 4, 2025 the Board of Directors of Palisade Bio, Inc. (the “Company”), upon the approval and recommendation of the Compensation Committee, approved and adopted a Phantom Unit Plan (the “Plan”) and related form of Phantom Unit Grant Notice and Award Agreement (collectively, the “Award Agreement”).

     

    Under the terms of the Plan, the Compensation Committee may grant compensatory awards to the Company’s employees, directors and consultants whose value shall be tied to the common stock of the Company, through the granting of up to 10,000,000 cash-settled phantom units, subject to the adjustment provisions of the Plan (collectively, the “Phantom Units”). The Plan was adopted without stockholder approval as the Phantom Units are exempt from the NASDAQ shareholder vote requirements.

     

    The Compensation Committee will determine the terms of any Phantom Units granted under the Plan, including the vesting and settlement schedule applicable to the Phantom Units at the time of each grant. Grantees of Phantom Units shall not by virtue of their receipt of Phantom Units have any ownership rights in shares of the Company’s common stock. The Plan shall continue for a period of ten years, after which no further Phantom Units may be awarded (although any Phantom Units awarded prior to the expiration of such 10-year period shall be unaffected by the termination of the Plan). The amendment and termination provisions of the Plan are substantially similar to those in the Company’s 2021 Equity Incentive Plan.

     

    Executive Officer and Director Grants

     

    Also on September 4, 2025, the following grants occurred under the Plan: J.D. Finley, the Company’s Chief Executive Officer, was granted 323,400 Phantom Units; Mitchell Jones, the Company’s Chief Medical Officer, was granted 289,000 Phantom Units; Ryker Willie, the Company’s Senior Vice President of Finance, was granted 137,600 Phantom Units; the Board Chair was granted 64,400 Phantom Units; and the other independent directors were each granted 37,600 Phantom Units.

     

    Vesting Schedules

     

    The Phantom Units for the executives will vest in twelve equal quarterly installments over three years (subject to each executive’s continuous service) with vesting dates of February 5, May 5, August 5, and November 5 each year, with the first vesting date to be November 5, 2025. The Phantom Units for the directors will vest in three annual installments over three years (subject to continuous service) with vesting dates of August 5 each year, with the first vesting date to be August 5, 2026.

     

    Accelerated Vesting

     

    For our executive officers, the Phantom Units granted to J.D. Finley, Ryker Willie, and Mitchell Jones are subject to additional vesting acceleration terms, a summary of which is provided below and the full details of which can be found within their respective amended employment agreements, which will be filed as exhibits to the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2025.

     

    For directors, they will receive 100% accelerated vesting if they are serving as a director of the Board on the date of a Liquidity Change of Control (as defined in the Plan).

     

     

     

     

    The foregoing description of the Plan and Award Agreement does not purport to be complete, and is qualified in its entirety by reference to the complete text of the Plan and Award Agreement, which will be filed as exhibits to the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2025.

     

    Payment Amount

     

    Payments upon the settlement of a vested Phantom Unit will equal the Fair Market Value of a share of the Company’s common stock as of the date of the applicable Trigger Event (as defined below).

     

    Trigger Events and Payment Schedule of Phantom Units for Executives

     

    For each vested Phantom Unit, the value of such Phantom Unit will be paid following the earliest Trigger Event on the schedule in the table below:

     

    Trigger Event   Payment Schedule
    Liquidity Change in Control   Payable in a lump sum, within 60 days.
    A termination of the executive’s service without cause or for good reason (other than within 12 months following a Liquidity Change in Control)   Payable in 12 substantially equal monthly installments with the first payment payable within 60 days.
    A termination of the executive’s service without cause or for good reason within 12 months following a Liquidity Change in Control   Payable in a lump sum, within 60 days.
    7th anniversary of Date of Grant   Payable in a lump sum, within 60 days.

     

    Any payments upon settlement of the Phantom Units will be subject to a six-month delay to the extent required under Section 409A of the Internal Revenue Code of 1986.

     

    Trigger Events and Payment Schedule of Phantom Units for Directors

     

    For each vested Phantom Unit, the value of such Phantom Unit will be paid following the earliest Trigger Event on the schedule in the table below:

     

    Trigger Event   Payment Schedule
    Termination of a director’s service with the Company for any reason   Payable in 12 substantially equal monthly installments with the first payment payable within 60 days.
    Liquidity Change in Control   Payable in a lump sum, within 60 days.
    7th anniversary of Date of Grant   Payable in a lump sum, within 60 days.

     

    Amendment to Employment Agreements

     

    Chief Executive Officer and Chief Financial Officer

     

    On September 4, 2025, the Company entered into an Amended and Restated Executive Employment Agreement with J.D. Finley, Chief Executive Officer and Chief Financial Officer (the “A&R Finley Agreement”).

     

    The material terms of the A&R Finley Agreement provide, among other things:

     

    ●Mr. Finley will continue to serve as Chief Executive Officer and Chief Financial Officer, reporting to the Board.

     

     

     

     

    ●Mr. Finley will receive a base salary of $575,000 per year, subject to Board review.
       
    ●Eligibility for a discretionary annual bonus of up to 50% of base salary, paid after determination of performance target achievement.
       
    ●Mr. Finley may receive annual and additional equity-based awards, which may include Phantom Units, at the Board’s discretion under the Company’s equity incentive plans.
       
    ●If subject to involuntary termination (without cause or for good reason) outside of the Change in Control Period (defined below), Mr. Finley will be entitled to receive: (i) 12 months’ base salary continuation; (ii) payment of COBRA premiums for up to 12 months; (iii) 100% acceleration of time-based equity vesting; and (iv) any unpaid annual bonus for a prior year.
       
    ●Upon an involuntary termination (without cause or for good reason) within the period commencing 3 months prior to and ending 12 months following a change in control of the Company (the “Change in Control Period”), Mr. Finley will be entitled to receive: (i) a lump sum payment equal to 24 months’ base salary and 2x target annual bonus; (ii) payment of COBRA premiums for up to 24 months; (iii) 100% acceleration of time-based equity awards; and (iv) any unpaid annual bonus for a prior year.

     

    These severance benefits are conditioned on compliance with non-competition, non-solicitation, and confidential information covenants, and execution of an effective release. The entire A&R Finley Agreement will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2025.

     

    Senior Vice President of Finance

     

    On September 4, 2025, the Company also entered into an Amended and Restated Executive Employment Agreement with Ryker Willie, Senior Vice President of Finance (the “A&R Willie Agreement”).

     

    The material terms of the A&R Willie Agreement provide, among other things:

     

    ●Mr. Willie will continue to serve as Senior Vice President of Finance, reporting to the Chief Executive Officer.
       
    ●Mr. Willie will receive an annual base salary of $298,500, with eligibility for review and adjustment by the Board.
       
    ●Mr. Willie may earn a discretionary annual bonus of up to 35% of base salary, subject to achievement of performance targets established by the Board.
       
    ●Eligibility to participate in Company benefit plans as well as annual and additional equity-based awards, which may include Phantom Units, granted at the Board’s discretion, under the Company’s equity incentive plans.
       
    ●If subject to an involuntary termination (without cause or for good reason) outside of the Change in Control Period, Mr. Willie will be entitled to receive: (i) a nine months’ base salary continuation; (ii) payment of COBRA premiums for up to nine months; and (iii) any unpaid annual bonus for a prior year.
       
    ●If subject to an involuntary termination (without cause or for good reason) during the Change in Control Period, Mr. Willie will be entitled to receive: (i) a lump sum severance equal to 18 months’ base salary and 1.5x target bonus; (ii) payment of COBRA premiums for up to 18 months; (iii) 100% acceleration of time-based equity awards; and (iv) any unpaid annual bonus for a prior year.

     

     

     

     

    These severance benefits are conditioned on compliance with non-competition, non-solicitation, and confidential information covenants, and execution of an effective release. The entire A&R Willie Agreement will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2025.

     

    Chief Medical Officer

     

    On September 4, 2025, the Company also entered into an Amended and Restated Executive Employment Agreement with Mitchell Jones, M.D., Ph.D., Chief Medical Officer (the “A&R Jones Agreement”).

     

    The material terms of the A&R Jones Agreement provide, among other things:

     

    ●Dr. Jones will continue to serve as Chief Medical Officer, reporting to the CEO.
       
    ●Dr. Jones will receive a base salary of $440,000 per year, subject to adjustment by the Board.
       
    ●He is eligible for a discretionary annual bonus of up to 40% of base salary, with the first year’s bonus not pro-rated.
       
    ●Dr. Jones is eligible for annual and additional equity-based awards, which may include Phantom Units, at the discretion of the Board, under the Company’s incentive plans.
       
    ●If subject to an involuntary termination (without cause or for good reason) outside of the Change in Control Period, Dr. Jones will be entitled to receive: (i) 12 months’ base salary continuation; (ii) payment of COBRA premiums for up to 12 months; and (iii) any unpaid annual bonus for a prior year.
       
    ●If subject to an involuntary termination (without cause or for good reason) during the Change in Control Period, Dr. Jones will be entitled to receive: (i) a lump sum payment of 24 months’ base salary and 2x target bonus; (ii) payment of COBRA premiums for up to 24 months; (iii) 100% acceleration of all time-based equity awards; and (iv) any unpaid annual bonus for a prior year.

     

    These severance benefits are conditioned on compliance with non-competition, non-solicitation, and confidential information covenants, and execution of an effective release. The entire A&R Jones Agreement will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2025.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: September 5, 2025 Palisade Bio, Inc.
         
        /s/ J.D. Finley
      By: J.D. Finley
        Chief Executive Officer

     

     

     

    Get the next $PALI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PALI

    DatePrice TargetRatingAnalyst
    2/2/2022$5.00Buy
    Ladenburg Thalmann
    8/31/2021$7.00Buy
    Maxim Group
    More analyst ratings

    $PALI
    SEC Filings

    View All

    SEC Form PRE 14A filed by Palisade Bio Inc.

    PRE 14A - PALISADE BIO, INC. (0001357459) (Filer)

    9/5/25 11:01:03 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Inc. filed SEC Form 8-K: Leadership Update

    8-K - PALISADE BIO, INC. (0001357459) (Filer)

    9/5/25 9:00:42 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by Palisade Bio Inc.

    EFFECT - PALISADE BIO, INC. (0001357459) (Filer)

    8/29/25 12:15:12 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PALI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD)

    First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies Patient dosing expected to commence in H2 2025; Topline data anticipated in Q1 2026 Continued progress toward Phase 2 IND submissions in Q1 2026 Carlsbad, CA, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade," "Palisade Bio," or the "Company"), a clinical-stage biopharmaceutical company developing precision therapies for autoimmune, inflammatory, and fibrotic diseases, today announced that it received a No Objection Letter ("NOL") from Health Canada for its Clinical Trial Application to evaluate PALI-2108, a first-in-class, ileocol

    9/5/25 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108

    – Moderated discussion with leading expert in Fibrostenotic Crohn's Disease (FSCD) and Inflammatory Bowel Diseases (IBD), Dr. Brian Feagan  – Segment provides further insight into the need for more effective treatment options for FSCD and how PALI-2108 may become a leader in the new frontier of IBD therapeutics – Access the segment here Carlsbad, CA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade," "Palisade Bio," or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the release of a Virtual Investor KOL C

    8/25/25 9:00:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108

    PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs) Extended half-life and local bioactivation support convenient once-daily dosing in ulcerative colitis (UC) and fibrostenotic Crohn's disease (FSCD) Colon tissue drug levels exceeded target thresholds 36 hours post-dose in completed Phase 1a MAD cohort Company advancing toward IND submission for Phase 2 study in H1 2026 Carlsbad, CA, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and

    8/7/25 9:15:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PALI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Williams Donald Allen bought $4,863 worth of Comon Stock (1,000 units at $4.86) (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    5/29/24 3:47:14 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Finley John David bought $4,810 worth of shares (1,000 units at $4.81), increasing direct ownership by 13% to 8,437 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    5/28/24 6:02:01 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Finley John David bought $4,692 worth of shares (10,000 units at $0.47), increasing direct ownership by 13% to 84,649 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    2/7/24 8:30:10 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PALI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Medical Officer Jones Mitchell Lawrence

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    9/5/25 9:00:35 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by CEO, CFO Finley John David

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    9/5/25 9:00:39 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Wei Binxian

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    9/5/25 9:00:37 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PALI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ladenburg Thalmann initiated coverage on Palisade Bio with a new price target

    Ladenburg Thalmann initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $5.00

    2/2/22 7:38:44 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Maxim Group initiated coverage on Palisade Bio with a new price target

    Maxim Group initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $7.00

    8/31/21 8:02:44 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PALI
    Leadership Updates

    Live Leadership Updates

    View All

    Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors

    Veteran clinical leader with successful track record and experience to help guide the Company's clinical strategy in Fibrostenotic Crohn's Disease and Ulcerative Colitis Carlsbad, CA, July 09, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it has appointed Emil Chuang, MB BS FRACP to its Board of Directors. Dr. Chuang is a pediatric gastroenterologist with nearly 25 years of pharmaceutical and clinical experience spanning large pharma, biotech, therapeutics, medical nu

    7/9/25 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

    Carlsbad, CA, Dec. 17, 2024 (GLOBE NEWSWIRE) --  Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade," "Palisade Bio" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases, today announced the appointment of Brian G. Feagan, MD, FRCPC, to its Clinical Advisory Board. Dr. Feagan is a distinguished gastroenterologist with over 30 years of experience in the design, conduct, and execution of large-scale randomized controlled trials (RCTs) for Crohn's disease (CD) and ulcerative colitis (UC). He has served as Principal Investigator in more than 140 multi-center RCTs and has dedicated mu

    12/17/24 8:30:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Appoints Margery Fischbein to its Board of Directors

    Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio" or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it has appointed Margery Fischbein to its Board of Directors. Ms. Fischbein is a highly experienced healthcare investment banker and accomplished biotechnology industry executive. "We are excited to welcome Ma

    5/7/24 8:30:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PALI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Palisade Bio Inc.

    SC 13G - PALISADE BIO, INC. (0001357459) (Subject)

    11/14/24 3:35:13 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Palisade Bio Inc. (Amendment)

    SC 13G/A - PALISADE BIO, INC. (0001357459) (Subject)

    2/14/24 2:54:03 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Palisade Bio Inc. (Amendment)

    SC 13G/A - PALISADE BIO, INC. (0001357459) (Subject)

    2/13/24 8:10:04 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PALI
    Financials

    Live finance-specific insights

    View All

    Palisade Bio (Nasdaq: PALI) Announces Analysis Demonstrating LB1148 Reduced the Extent and Severity of Post-Surgical Intraabdominal Adhesions by 93%

    Data from Pooled-Analysis of Enteral Protease Inhibitor LB1148 Demonstrated 72% Reduction in the Risk of Adhesion Formation in Patients Undergoing Bowel Resection Surgery Company to Host Conference Call on Wednesday, March 16, 2022, at 8:30 a.m. EDT CARLSBAD, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced data from a Pooled-Analysis of Studies LBS-IST-POI-101 and LBS-POI-201-CN (PROFILE-CN.) These data are featured today at the Next Big Thing session of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 202

    3/16/22 8:00:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care